BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 32786329)

  • 21. Potential strategies for combating COVID-19.
    Shamim S; Khan M; Kharaba ZJ; Ijaz M; Murtaza G
    Arch Virol; 2020 Nov; 165(11):2419-2438. PubMed ID: 32778950
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A critical evaluation of glucocorticoids in the management of severe COVID-19.
    Solinas C; Perra L; Aiello M; Migliori E; Petrosillo N
    Cytokine Growth Factor Rev; 2020 Aug; 54():8-23. PubMed ID: 32616381
    [TBL] [Abstract][Full Text] [Related]  

  • 23. SARS-CoV-2: An immunogenetics call to arms.
    Clark B; Poulton K
    Int J Immunogenet; 2020 Aug; 47(4):319-323. PubMed ID: 32654378
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of early treatment with sarilumab in hospitalised adults with COVID-19 presenting cytokine release syndrome (SARICOR STUDY): protocol of a phase II, open-label, randomised, multicentre, controlled clinical trial.
    León López R; Fernández SC; Limia Pérez L; Romero Palacios A; Fernández-Roldán MC; Aguilar Alonso E; Pérez Camacho I; Rodriguez-Baño J; Merchante N; Olalla J; Esteban-Moreno MÁ; Santos M; Luque-Pineda A; Torre-Cisneros J
    BMJ Open; 2020 Nov; 10(11):e039951. PubMed ID: 33191263
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Successful use of methylprednisolone for treating severe COVID-19.
    Liu J; Zheng X; Huang Y; Shan H; Huang J
    J Allergy Clin Immunol; 2020 Aug; 146(2):325-327. PubMed ID: 32479759
    [No Abstract]   [Full Text] [Related]  

  • 26. New (re)purpose for an old drug: purinergic modulation may extinguish the COVID-19 thromboinflammatory firestorm.
    Kanthi Y; Knight JS; Zuo Y; Pinsky DJ
    JCI Insight; 2020 Jul; 5(14):. PubMed ID: 32530438
    [TBL] [Abstract][Full Text] [Related]  

  • 27. COVID-19, pulmonary mast cells, cytokine storms, and beneficial actions of luteolin.
    Theoharides TC
    Biofactors; 2020 May; 46(3):306-308. PubMed ID: 32339387
    [No Abstract]   [Full Text] [Related]  

  • 28. Targeting T-cell senescence and cytokine storm with rapamycin to prevent severe progression in COVID-19.
    Omarjee L; Janin A; Perrot F; Laviolle B; Meilhac O; Mahe G
    Clin Immunol; 2020 Jul; 216():108464. PubMed ID: 32405269
    [No Abstract]   [Full Text] [Related]  

  • 29. Immunosuppression during the COVID-19 pandemic in neuromyelitis optica spectrum disorders patients: A new challenge.
    Carnero Contentti E; Correa J
    Mult Scler Relat Disord; 2020 Jun; 41():102097. PubMed ID: 32278860
    [No Abstract]   [Full Text] [Related]  

  • 30. Ursodeoxycholic acid as a candidate therapeutic to alleviate and/or prevent COVID-19-associated cytokine storm.
    Abdulrab S; Al-Maweri S; Halboub E
    Med Hypotheses; 2020 Oct; 143():109897. PubMed ID: 32505909
    [No Abstract]   [Full Text] [Related]  

  • 31. Potential Treatments for COVID-19 Related Cytokine Storm - Beyond Corticosteroids.
    Miao Y; Fan L; Li JY
    Front Immunol; 2020; 11():1445. PubMed ID: 32612616
    [No Abstract]   [Full Text] [Related]  

  • 32. Emerging treatments in COVID-19: Adverse drug reactions including drug hypersensitivities.
    Manjaly Thomas ZR; Leuppi-Taegtmeyer A; Jamiolkowski D; Steveling-Klein E; Bellutti-Enders F; Scherer Hofmeier K; Hartmann K
    J Allergy Clin Immunol; 2020 Oct; 146(4):786-789. PubMed ID: 32710973
    [No Abstract]   [Full Text] [Related]  

  • 33. Cytokine Storm in COVID-19: "When You Come Out of the Storm, You Won't Be the Same Person Who Walked in".
    Castelli V; Cimini A; Ferri C
    Front Immunol; 2020; 11():2132. PubMed ID: 32983172
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Should we target the virus, the cell or the disease?].
    Nisole S; Saulnier A; Gatignol A
    Virologie (Montrouge); 2020 Jun; 24(3):135-141. PubMed ID: 32648548
    [No Abstract]   [Full Text] [Related]  

  • 35. COVID-19: Small-Molecule Clinical Trials Landscape.
    Ferreira LLG; Andricopulo AD
    Curr Top Med Chem; 2020; 20(18):1577-1580. PubMed ID: 32862824
    [No Abstract]   [Full Text] [Related]  

  • 36. Immune Alterations in a Patient with SARS-CoV-2-Related Acute Respiratory Distress Syndrome.
    Bouadma L; Wiedemann A; Patrier J; Surénaud M; Wicky PH; Foucat E; Diehl JL; Hejblum BP; Sinnah F; de Montmollin E; Lacabaratz C; Thiébaut R; Timsit JF; Lévy Y
    J Clin Immunol; 2020 Nov; 40(8):1082-1092. PubMed ID: 32829467
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treating COVID-19 with colchicine in community healthcare setting.
    Della-Torre E; Della-Torre F; Kusanovic M; Scotti R; Ramirez GA; Dagna L; Tresoldi M
    Clin Immunol; 2020 Aug; 217():108490. PubMed ID: 32492478
    [No Abstract]   [Full Text] [Related]  

  • 38. SARS-CoV-2: a time for clear and immediate action.
    Poland GA
    Lancet Infect Dis; 2020 May; 20(5):531-532. PubMed ID: 32243818
    [No Abstract]   [Full Text] [Related]  

  • 39. Use of inhaled corticosteroids in asthma and coronavirus disease 2019: Keep calm and carry on.
    Lipworth B; Chan R; Kuo CR
    Ann Allergy Asthma Immunol; 2020 Nov; 125(5):503-504. PubMed ID: 32585180
    [No Abstract]   [Full Text] [Related]  

  • 40. Emergence of novel coronavirus and progress toward treatment and vaccine.
    Khan MM; Noor A; Madni A; Shafiq M
    Rev Med Virol; 2020 Jul; 30(4):e2116. PubMed ID: 32495979
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.